Are surrogate markers adequate to assess cardiovascular disease drugs?
Temple
R
R
Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA. Temple@CDER.fda.gov
D015415:Biomarkers; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004341:Drug Evaluation; D006801:Humans; D012306:Risk; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D015415:Biomarkers; D002317:Cardiovascular Agents